中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
18期
7-9
,共3页
婴幼儿哮喘%布地奈德%阶梯雾化吸入治疗%临床价值
嬰幼兒哮喘%佈地奈德%階梯霧化吸入治療%臨床價值
영유인효천%포지내덕%계제무화흡입치료%림상개치
Infantile asthma%Budesonide%Escalation aerosol inhalation therapy%Clinical value
目的：比较布地奈德混悬液阶梯雾化吸入和布地奈德气雾剂+贮雾罐吸入治疗婴幼儿哮喘的效果,为改善婴幼儿哮喘提供依据。方法106例哮喘婴幼儿随机分为观察组和对照组,各53例。观察组采用布地奈德混悬液阶梯雾化吸入方案；对照组采用布地奈德气雾剂+贮雾罐吸入治疗。在入院时,治疗12、24、28周时进行症状评分,并在48周随访结束时,统计患儿吸入依从率、发作就医次数、发作总天数、缓解期药物用量。结果两组经治疗,症状评分均较入院时显著改善,差异具有统计学意义(P<0.05)。其中：观察组治疗12、24、48周时症状评分分别为(0.63±0.35)、(0.61±0.32)、(0.52±0.36)分,均显著低于对照组(t 值分别为6.436、6.418、6.835, P<0.05)。观察组依从率为94.34%,显著高于对照组77.36%(P<0.05)。观察组发作就医次数、发作总天数、缓解期药物使用量分别为(2.2±1.4)次、(12.8±6.5) d、(0.18±0.13)mg/d,均显著低于对照组(P<0.05)。结论阶梯雾化吸入可以显著改善婴幼儿哮喘的症状评分,提高患儿的依从率,减少治疗期间发作次数和发作天数,并减低布地奈德的使用量,是目前临床上治疗婴幼儿哮喘的一种相对理想的方法。
目的：比較佈地奈德混懸液階梯霧化吸入和佈地奈德氣霧劑+貯霧罐吸入治療嬰幼兒哮喘的效果,為改善嬰幼兒哮喘提供依據。方法106例哮喘嬰幼兒隨機分為觀察組和對照組,各53例。觀察組採用佈地奈德混懸液階梯霧化吸入方案；對照組採用佈地奈德氣霧劑+貯霧罐吸入治療。在入院時,治療12、24、28週時進行癥狀評分,併在48週隨訪結束時,統計患兒吸入依從率、髮作就醫次數、髮作總天數、緩解期藥物用量。結果兩組經治療,癥狀評分均較入院時顯著改善,差異具有統計學意義(P<0.05)。其中：觀察組治療12、24、48週時癥狀評分分彆為(0.63±0.35)、(0.61±0.32)、(0.52±0.36)分,均顯著低于對照組(t 值分彆為6.436、6.418、6.835, P<0.05)。觀察組依從率為94.34%,顯著高于對照組77.36%(P<0.05)。觀察組髮作就醫次數、髮作總天數、緩解期藥物使用量分彆為(2.2±1.4)次、(12.8±6.5) d、(0.18±0.13)mg/d,均顯著低于對照組(P<0.05)。結論階梯霧化吸入可以顯著改善嬰幼兒哮喘的癥狀評分,提高患兒的依從率,減少治療期間髮作次數和髮作天數,併減低佈地奈德的使用量,是目前臨床上治療嬰幼兒哮喘的一種相對理想的方法。
목적：비교포지내덕혼현액계제무화흡입화포지내덕기무제+저무관흡입치료영유인효천적효과,위개선영유인효천제공의거。방법106례효천영유인수궤분위관찰조화대조조,각53례。관찰조채용포지내덕혼현액계제무화흡입방안；대조조채용포지내덕기무제+저무관흡입치료。재입원시,치료12、24、28주시진행증상평분,병재48주수방결속시,통계환인흡입의종솔、발작취의차수、발작총천수、완해기약물용량。결과량조경치료,증상평분균교입원시현저개선,차이구유통계학의의(P<0.05)。기중：관찰조치료12、24、48주시증상평분분별위(0.63±0.35)、(0.61±0.32)、(0.52±0.36)분,균현저저우대조조(t 치분별위6.436、6.418、6.835, P<0.05)。관찰조의종솔위94.34%,현저고우대조조77.36%(P<0.05)。관찰조발작취의차수、발작총천수、완해기약물사용량분별위(2.2±1.4)차、(12.8±6.5) d、(0.18±0.13)mg/d,균현저저우대조조(P<0.05)。결론계제무화흡입가이현저개선영유인효천적증상평분,제고환인적의종솔,감소치료기간발작차수화발작천수,병감저포지내덕적사용량,시목전림상상치료영유인효천적일충상대이상적방법。
Objective To compare the effects between budesonide suspension in escalation aerosol inhalation therapy and budesonide aerosol+spacer inhalation therapy in the treatment of infantile asthma, in order to provide reference for improving infantile asthma. Methods A total of 106 children with infantile asthma were randomly divided into observation group and control group, with 53 cases in each group. The observation group received budesonide suspension in escalation aerosol inhalation therapy, and the control group received budesonide aerosol+spacer inhalation therapy. Symptoms scores were taken in admission, 12, 24, 28 weeks of treatment. Compliance rate of inhalation, onset medical visit times, total onset time, drug dose in catabasis were summarized at the end of follow-up in 48 weeks. Results After treatment, both groups had improved symptom score than that in admission, and the difference had statistical significance (P<0.05). Symptom score in 12, 24, 48 weeks were (0.63±0.35), (0.61±0.32), and (0.52±0.36) points in the observation group. Those were much lower than the control group (t values were 6.436, 6.418, 6.835, P<0.05). The observation group had higher compliance rate as 94.34% than 77.36% of the control group (P<0.05). The observation group had much lower onset medical visit times, total onset time, drug dose in catabasis as (2.2±1.4) times, (12.8±6.5) d, and (0.18±0.13) mg/d than the control group (P<0.05). Conclusion Escalation aerosol inhalation therapy can effectively improve symptom score and compliance of infantile asthma, and reduce onset times and budesonide dose in treatment. This is an ideal method in present clinical treatment for infantile asthma.
